Psychedelic-assisted psychotherapy

Abstract

Objective

To review psychedelic-assisted psychotherapy (PAP), including its principles, mechanisms of action, safety considerations, and current state of evidence relevant to Canadian primary care.

Sources of information

The evidence of PAP is evolving and is primarily derived from phase 2 and 3 clinical trials in specialized research settings. Systematic reviews and meta-analyses suggest potential benefit for selected conditions, though heterogeneity is high, and long-term comparative effectiveness relative to standard treatments remains uncertain.

Main message

PAP combines structured psychotherapy with supervised administration of psychedelic medicines in controlled settings. While not a first-line treatment or a primary care–delivered intervention, family physicians may encounter patients seeking information, referral, or guidance regarding PAP and should be familiar with basic evidence, contraindications, access pathways, and harm-reduction considerations.

Conclusion

PAP represents an emerging intervention with potential clinical relevance for select patients. As research and regulatory frameworks continue to evolve in Canada, cautious, evidence-informed engagement by family physicians is warranted.

Psychedelic-assisted psychotherapy (PAP) is a novel treatment approach that combines psychotherapy with psychedelic medicines in controlled environments to promote deep emotional processing, new perspectives, and long-term positive change. The objective of this article is to provide an overview of PAP, its principles, mechanisms of action, safety, and current evidence. This article does not advocate for PAP as a first-line treatment for mental health conditions (including treatment-resistant depression [TRD] and posttraumatic stress disorder [PTSD]) within family medicine, but aims to equip family physicians (FPs) with evidence-informed knowledge to counsel patients, assess contraindications, navigate referral pathways, and apply harm-reduction principles in a rapidly evolving therapeutic and regulatory landscape.

Case description

A 52-year-old woman with a history of recurrent major depressive disorder presents to her FP to discuss ongoing symptoms of low mood, anhedonia, and hopelessness despite multiple trials of antidepressant medications and psychotherapy. She has no history of psychosis or bipolar disorder and is medically stable. During the visit, she asks about psilocybin-assisted therapy, noting that she has encountered media coverage and online discussions describing its potential benefits for TRD.

Sources of information

The evidence base for PAP is emerging, with most published data from phase 2 and 3 trials conducted in specialized research settings with carefully selected participants and intensive psychotherapeutic support. Recent systematic reviews and meta-analyses suggest that PAP is associated with moderate to large short-term reductions in depressive and PTSD symptoms compared with control conditions, though heterogeneity is high and long-term comparative effectiveness relative to standard treatments remains uncertain.^1-4

This paper focuses on psilocybin and 3,4-methylenedioxymethamphetamine (MDMA), as these 2 psychedelic medicines have the most robust evidence to date and are currently approved by Health Canada through the Special Access Program for treatment of PTSD, end-of-life existential distress, and TRD.⁵

Across numerous studies, psilocybin has shown promising preliminary evidence for greater antidepressant efficacy in TRD and end-of-life distress versus trial comparator arms.^1-4 For example, a meta-analysis reported pooled depression remission rates of 45% with psilocybin compared with 22% in comparator arms,¹ while another found a large reduction in depressive symptoms (Hedges g=1.05).³ Two phase 3 clinical trials investigating psilocybin therapy for TRD have reported positive results, although full peer-reviewed publication of these findings is pending.⁶ There are also multiple phase 2 trials investigating psilocybin for TRD,⁷ major depressive disorder,⁸ alcohol use disorder,⁹ PTSD,¹⁰ and end-of-life distress.^11,12 There are currently 28 registered clinical trials under way in Canada investigating psilocybin-assisted therapy for multiple psychiatric and neurologic conditions.

Similarly, MDMA has shown promise in numerous studies that compared its efficacy in treating PTSD versus placebo pharmacotherapy or psychotherapy alone.^3,4,13 One meta-analysis found a large effect size of MDMA-assisted therapy on PTSD symptoms compared to placebo (Hedges g=1.24).³ Another reported that participants were 1.59 times as likely to achieve a clinical response and 2.32 times as likely to achieve remission compared with control groups.¹³ Two phase 3 trials of MDMA therapy for PTSD^14,15 are complete and while initially rejected by the United States Food and Drug Administration in 2024, re-review and re-scheduling is possible in 2026. Newer MDMA pilot trials have shown safety and early efficacy for alcohol use disorder,¹⁶ social anxiety in adults with autism,¹⁷ and end-of-life anxiety.¹⁸

Main message

PAP is a modality that combines psychotherapy with psychedelic medicines to catalyze introspection, overcome experiential avoidance, and aid emotional processing and consciousness expansion in the service of healing.

Psilocybin: a promising therapeutic agent. Psilocybin is a naturally occurring psychedelic compound that is found in over 200 species of mushrooms that grow around the world.¹⁹ Its active metabolite, psilocin, chemically resembles serotonin and agonizes the 5-HT2A receptor in the cortex,^20,21 leading to a host of perceptual changes and dramatic shifts in emotional and cognitive processing. Biologically, psilocybin is hypothesized to influence neuroplasticity, inflammatory signalling, and learning processes based primarily on preclinical and early translational research. Evidence for increased neuroplasticity and altered critical learning periods derives largely from animal and in vitro models, with limited direct confirmation in human clinical populations.^22-24 Psychologically, psilocybin therapy promotes emotional release and resolution, decreases experiential avoidance, and increases mindfulness, creativity, openness,²⁵ and connectedness to oneself, others, and the world.²⁶ This enables individuals to rewire reinforced, maladaptive patterns of feelings, thoughts, and actions, promoting cognitive and psychological flexibility.²⁷ Spiritually, psychedelics can induce mystical experiences,²⁸ fostering a sense of interconnectedness, awe, and increased nature relatedness,²⁹ culminating in a profound sense of love and unity. These biologic, psychologic, and spiritual mechanisms converge to facilitate deep emotional processing, innovative shifts in thinking, behavioural changes, and long-term positive gains in individuals undergoing PAP.

MDMA-assisted psychotherapy: breakthroughs in treating PTSD. MDMA’s hypothesized therapeutic mechanisms include enhancing trust, as well as increasing empathy and self-compassion.³⁰ These mechanisms allow for improved engagement with exposure therapy and memory retrieval or reconsolidation.³¹ Neurobiologic effects include the release of oxytocin, dopamine, and cortisol, promoting bonding and social reward learning.³² With phase 3 trials showing improvements in depression scores and functional impairment,^14,15 MDMA-assisted psychotherapy offers a groundbreaking approach to treating PTSD.

Psychedelic-assisted psychotherapy preparation, dosing, and integration. PAP is grounded in the principles of set and setting, which emphasize the importance of establishing a supportive environment, building trust, and fostering a willingness to confront and process challenging emotions. The therapy consists of 3 phases: preparation, dosing, and integration. Prior to dosing, patients undergo a thorough medical and psychiatric screening, informed consent, and preparatory psychoeducation about the risks, benefits, and experimental nature of the treatment. Patients also engage in multiple sessions with their therapists to establish therapeutic rapport, clarify intentions, and develop a personalized approach. The medicine session involves administration of a controlled dose of a psychedelic substance in a monitored clinical setting with trained therapists present for psychological support and physiological safety. Following dosing, integration psychotherapy focuses on consolidating insights, supporting emotional processing, and translating experiences into sustained behavioural and psychological change that can be applied to daily life.

Role of psychedelic-assisted psychotherapy providers. PAP providers, including therapists and physicians, play a crucial role in delivering safe and effective PAP by helping patients navigate their experiences and emotions. The quality of the therapeutic alliance is an important predictor of treatment outcomes in nonpsychedelic psychotherapy³³ and may be particularly salient in psychedelic-assisted care, given the heightened suggestibility associated with these interventions. Providers must also be familiar with the psychedelic landscape, including drug interactions, medical monitoring, harm-reduction principles, and the ability to distinguish spiritual experiences from psychopathology.³⁴ Safeguards such as standardized training, supervision, accreditation, and clinical practice guidelines are essential to ensure patient safety and provider accountability.

Implications for family physicians. FPs routinely care for patients experiencing psychological and existential distress, including TRD and distress associated with serious or life-limiting illness. In these contexts, patients may seek alternatives when conventional treatments have been ineffective, poorly tolerated, or no longer align with their goals of care.

Although PAP will not be delivered by most FPs, they play a critical role in helping patients explore emerging treatment options within an evidence-informed and ethically grounded framework. Public interest in psychedelic therapies has increased substantially in recent years, and patients are increasingly encountering and seeking information about PAP outside the clinical encounter.³⁵

FPs are well positioned to support informed, values-based decision making by contextualizing interest in PAP within the broader treatment landscape, clarifying patient goals, and addressing uncertainty, media enthusiasm, and uneven access. This role is particularly relevant for patients with TRD or serious illnesses, for whom questions of meaning, dignity, and quality of life often shape treatment preferences.³⁶

Key responsibilities include identifying potential contraindications within the scope of primary care, supporting realistic expectations regarding benefits and risks, and facilitating referral to regulated clinical or research-based PAP programs when appropriate. FPs also play an essential longitudinal role before and after PAP, including ongoing monitoring, medication review, and support with integration into patients’ broader care plans.^37,38 Box 1 outlines screening questions for providers considering PAP for their patients.^5,39-43

Box 1. Screening questions for physicians considering psychedelic-assisted psychotherapy for their patients.

1. Diagnosis and treatment history*

   • Have you been diagnosed with a psychiatric disorder that is resistant to conventional treatments (eg, TRD or PTSD)?
   • Which different evidence-based treatments have you tried for your condition?
   • Have you been diagnosed with cancer or another terminal illness?
2. Medical and psychiatric history

   • Do you have a personal history of or first-degree relative with a history of psychotic disorders, bipolar disorder, or borderline personality disorder? (These conditions are generally contraindications for psychedelic therapy due to the increased risk of exacerbation or psychological distress.)^39-41
   • Do you have any uncontrolled cardiovascular conditions? (Psychedelics can increase heart rate and blood pressure, posing risks for patients with cardiovascular issues.)^41,42
   • Are you pregnant or breastfeeding? Do you have an intention to get pregnant? (There is insufficient evidence to appropriately assess risk in these populations.)^41,42
3. Current medications

   • Are you currently taking any medications that might interact with psychedelics? (Certain medications, particularly those affecting serotonin levels, may interact adversely with psychedelics.)⁴³
4. Support system

   • Do you have a reliable support system in place? (A strong support system is crucial for the integration phase and for managing any potential adverse effects.)⁴³

PTSD—posttraumatic stress disorder, TRD—treatment-resistant depression.

*Presently, there are no standardized national guidelines for training or clinical delivery, and available programs vary widely in scope and quality. We have opted not to include a formal table of recommended programs or patient-facing clinics, as we cannot attest to their quality or safety. Instead, we highlight ClinicalTrials.gov (https://clinicaltrials.gov) and Health Canada’s Special Access Program⁵ as the most reliable pathways for patients seeking regulated access, and we encourage clinicians to critically evaluate training programs based on their scope, accreditation, and evidence-based content.

FPs should not initiate or supervise PAP outside established regulatory frameworks, nor provide clearance for psychedelic use without specialist assessment. However, as trusted longitudinal clinicians, they remain central to patient safety, continuity of care, and ethical navigation of an evolving therapeutic landscape.

Patient access and provider education. Despite the growing evidence supporting PAP, as well as increased media popularity, regulated patient access remains limited. Classic psychedelics, such as lysergic acid diethylamide, N,N-dimethyltryptamine, and psilocybin, are Schedule III drugs under the Controlled Drugs and Substances Act, while MDMA and ketamine are Schedule I.⁴⁴ FPs should be aware that patients can access research trials through ClinicalTrials.gov (https://clinicaltrials.gov) or through referral via Health Canada’s Special Access Program.⁵ Clinicians may also encounter patients considering PAP outside of regulated or research settings and should be prepared to apply harm-reduction principles when counselling patients regarding safety and appropriate access. A physician who can set realistic expectations regarding access, risks, and uncertainty may help to reduce misinformation and inappropriate self-directed use. To address the need for provider education, various training opportunities can be found from the Michener Foundations of Psychedelic Psychotherapy Program at the University Health Network in Toronto, Ont; TheraPsil in Victoria, BC; California Institute of Integral Studies in San Francisco; Vancouver Island University in BC; and the University of Ottawa in Ontario.

Safety of psychedelic therapy. Psychedelic therapy is considered safe when administered by trained professionals in a controlled environment. Psychedelics such as MDMA and psilocybin have very low toxicity and a low risk of dependency.⁴⁵ Thorough screening is critical to ensuring patient safety and identifying potential risks and contraindications through a comprehensive medical and psychiatric history. A detailed life review may also be necessary to generate a thorough understanding of the patients’ biological, psychological, and spiritual considerations for therapy. Patient red flags must be explored, including difficulty building trust, setting unrealistic expectations, or having inadequate supports. Adverse events during psilocybin and MDMA sessions are common but typically mild, transient, and self-limiting. Common adverse events include tachycardia, hypertension, nausea, headaches, anxiety, and dissociation.⁴⁶ Additionally, suicidal ideation and behaviour have also been infrequently documented as serious adverse events (predominantly in participants with a history of suicidal ideation or attempts).⁴⁷ While rare and seen more outside of clinical contexts, other challenging symptoms can occur, which include destabilization, return of symptoms, profound shifts in worldview, emergence of traumatic events, persistent dissociation, and hallucinogen persisting perception disorder.^48,49 The possibility adverse effects and the experimental nature of this treatment need to be emphasized to the patient as there remain potential unknown risks. An aftercare plan for ongoing therapeutic support should also be available. Despite these potential risks, with proper screening, preparation (set and setting), and support, psychedelic therapy can be a safe and effective treatment approach for individuals seeking an accelerated depth-oriented psychotherapeutic process with potential for long-term benefit.

Case resolution

The FP explores the patient’s understanding of PAP, her treatment goals, and prior care experiences. Together, they review the current evidence, uncertainties, and regulatory status of psilocybin therapy in Canada. The physician assesses potential contraindications within the scope of primary care, discusses alternative evidence-based options, and provides guidance regarding referral to regulated clinical or research programs. The FP continues to provide longitudinal support, including medication management, symptom monitoring, and follow-up as the patient considers next steps.

Conclusion

PAP is a promising treatment approach that combines psychotherapy with psychedelic medicines to promote deep emotional processing, new insights, and long-term positive change. This work represents the meeting of medicine and spirituality in the pursuit of connection and meaning-making on both sides of the stethoscope. This emerging model offers a unique opportunity for healing and growth, addressing the whole person—body, mind, and spirit—and places trust in the inner healing wisdom of the patient. If efficacy after 1 or 2 dosing sessions is sustained, this model may challenge reliance on prolonged daily pharmacotherapy and represent a meaningful shift in mental health treatment. While challenges and risks exist, cautious optimism is warranted as research continues to uncover the therapeutic potential and limitations of PAP.

As access to PAP evolves in Canada, FPs will increasingly encounter patients seeking information, guidance, or referral. Education for patients, families, and clinicians is essential to support evidence-informed discussions, appropriate screening for contraindications, and navigation of emerging access pathways. Ongoing attention to safety, uncertainty, and ethical considerations will be required to ensure that PAP is integrated cautiously and appropriately within the broader landscape of mental health care.

Editor’s key points

• ▸ Psychedelic-assisted psychotherapy (PAP) is a promising treatment approach combining psychotherapy with psychedelic medicines to promote deep emotional processing, new insights, and long-term positive change.

• ▸ As access to PAP evolves in Canada, family physicians will increasingly encounter patients seeking information, guidance, or referral. Education for patients, families, and clinicians is essential to support evidence-informed discussions, appropriate screening for contraindications, and navigation of emerging access pathways.

• ▸ Ongoing attention to safety, uncertainty, and ethical considerations will be required to ensure that PAP is integrated cautiously and appropriately within the broader landscape of mental health care.